Objectives: Gemcitabine is a potent radiosensitizer. When combined with standard radiotherapy (XRT) the gemcitabine dose must be reduced to about 10% of its conventional dose. Oxaliplatin and erlotinib also have radiosensitizing properties. Oxaliplatin and gemcitabine have demonstrated synergy in vitro. We aimed to determine the maximum tolerated dose of oxaliplatin and gemcitabine with concurrent XRT, then oxaliplatin, gemcitaibine, and erlotinib with XRT in the treatment of locally advanced and low-volume metastatic pancreatic or biliary cancer.
A significant fraction of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis with a median overall survival (OS) in the range of 9 to 12 months. 1 Despite assiduous research, there has been relatively little advancement in the treatment of locally advanced pancreatic cancer. Recently there has been significant debate about the relative effectiveness of chemoradiotherapy versus chemotherapy alone. 2 However, the consequences of failure to control local disease should not be underestimated; uncontrolled primary disease has been associated with pain, nausea, vomiting, weight loss, obstruction, and decreased survival. 3 A number of studies have investigated chemoradiotherapy in locally advanced pancreatic cancer. Cancer and leukemia group B conducted a phase II trial of low-dose twice-weekly gemcitabine (60 mg/m 2 ) and concurrent radiation [radiotherapy (XRT), 50.4 Gy] with considerable toxicity and a median OS of 8.2 months. 4 There has been similar toxicity in other phase II trials using higher doses of gemcitabine administered once or twice weekly with relatively small radiation fields. As an example, a European phase II study tested weekly gemcitabine (100 mg/m 2 as a continuous infusion over 24 h) plus concurrent XRT (50.4 Gy), followed by 5 cycles of standard-dose gemcitabine, in patients with locally advanced pancreatic cancer. Grade 3 or 4 toxicity was observed in half the patients, but the median OS was 15.5 months and 25% of patients were alive at 2 years. 5 Oxaliplatin has synergistic cytotoxicity when combined with gemcitabine in human cancer cell lines in vitro or in xenografts. 6 Several clinical trials have demonstrated the efficacy of oxaliplatin and gemcitabine in various solid tumors, including pancreatic cancer, with response rates ranging from 10% to 30%, but no improvement in OS has been demonstrated. [7] [8] [9] Two recent phase 1 clinical trials in pancreatic cancer demonstrated the feasibility of combining oxaliplatin and gemcitabine with concurrent XRT encompassing narrower radiation fields. 10, 11 Our aim was to define the safety and tolerability of gemcitabine and oxaliplatin given on a once-weekly schedule with full doses of XRT for maximum local control, in the treatment of locally advanced and/or low-volume metastatic pancreatic cancer. A second phase of the study, which added erlotinib to the combination, was initiated but not completed due to termination of funding; results for the patients enrolled in that substudy are also presented.
METHODS

Patients
The study (National Clinical Trials Number, NCT00266097, local IRB# 04-MED-294-ORC) was performed at 2 academic centers. Eligible patients had biopsy-proven unresectable locally advanced or metastatic (at the discretion of the treating team) pancreatic carcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, a life expectancy > 2 months, adequate hematologic, renal and hepatic function, and a washout period of at least 3 weeks after previous anticancer therapy. During the second phase of the study (erlotinib phase), patients taking strong inducers or inhibitors of CYP3A were required to stop the medication to enter the study. The human subject committees at each participating center approved this study, and all patients provided a written informed consent before participation. All trial procedures were conducted in accordance with the principles established by the Helsinki Declaration.
Study Design
In the first part of the study, doses of gemcitabine and oxaliplatin were escalated using a modified 3+3 dose-escalation design ( Table 1 ). The second portion of the study added erlotinib (administered daily beginning on day 1) to the doses of gemcitabine and oxaliplatin that were 1 level below the recommended phase II dosing determined in the first part of the study. Gemcitabine was administered over 30 minutes, and oxaliplatin was administered over 2 hours weekly during XRT. Dose-limiting toxicity (DLT) was defined as any grade 4 toxicity or grade 3 toxicity causing a delay in treatment for more than a week. In addition, a dose level was deemed to be too toxic if dose reductions were required for 2 of the 3 patients in a given cohort. This modification of the standard 3+3 dose escalation-deescalation design prevents selection of a recommended phase II dose with a high rate of dose reductions. A dose level with 6 patients treated was considered intolerable if 2 occurrences of DLT were observed, or at least 1 DLT and dose reduction in at least 2 patients with the prior level declared the maximum tolerated dose (MTD). Gemcitabine and oxaliplatin dose reduction was allowed, with 20% dose reduction for grade 3 and 40% reduction for grade 4 toxicity. All agents were held if XRT was held for toxicity. In addition, all therapy was held for a weight loss of 15% or more.
XRT was administered in fractions of 1.8 Gy to a total dose of 50.4 Gy using conformal planning and a multifield technique. Gross tumor volume was defined as the tumor as visualized on computed tomography or magnetic resonance imaging or as defined by operative findings including the pancreatic mass and any lymph nodes measuring > 1.5 cm. Clinical target volume was defined by expanding the gross tumor volume by 1 to 1.5 cm in directions for which there is no anatomic barrier to microscopic spread. An additional margin of at least 1.0 cm was added to the clinical target volume for setup error and patient movement.
Safety evaluations were made at baseline and at weekly visits and included history and physical examinations, laboratory panels, and measurements of CA 19-9 at the outset and at the end of XRT. Response assessment by CT or magnetic resonance imaging was done 1 month after the completion of study therapy according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). Adverse events were scored according to the National Cancer Institute Common Terminology Criteria of Adverse Events (CTCAE v3.0).
Descriptive analyses were performed for all the demographic and analytic data. Categorical data were summarized using frequency tables and summary statistics such as mean, median, SD, and range were obtained for continuous data. Survival data were analyzed using the Kaplan-Meier statistic.
RESULTS
A total of 18 patients were treated as per this protocol ( Table 2 ). All had pancreatic cancer. The median age was 60. Four patients had undergone chemotherapy before the study treatment. Most of the tumors were in the head of the pancreas. One patient, who had progressed on gemcitabine-based chemotherapy, had low-volume metastatic disease. Table 3 describes grade 3 and 4 toxicities. One DLT (grade 4 elevated aspartate transaminase evidence of cholangitis) occurred in a patient at dose level 3, and a dose reduction occurred in 1 patient. This dose level was expanded to 6 patients and no other patients experienced a DLT or dose reduction. One patient experienced a DLT and 1 patient a dose reduction at dose level 4, the highest dose level evaluated. After expansion of this dose level, the erlotinib study began, as described below.
Common grade 1 and 2 toxicities were nausea, vomiting, diarrhea, weight loss, thrombocytopenia, and leukopenia. The most commonly encountered grade 3 toxicities were nausea (22%), elevated transaminases (17%), leucopenia (17%), and hyperglycemia (17%). Treatment delays and subsequent dose reductions occurred at dose level 1 (n = 1), dose level 2 (n = 2), dose level 3 (n = 2 of 6, one of which was a DLT), and dose level 4. The highest tested combination was gemcitabine 200 mg/m 2 weekly, oxaliplatin 50 mg/m 2 weekly, and XRT 50.4 Gy over 5 to 6 weeks, which produced manageable toxicity and represents the dose we would recommend for further evaluation.
All 18 patients completed XRT and each was evaluable for response assessment (Table 4 ). Responses included 1 partial response, 1 complete response, and 14 (78%) with stable Five patients were treated in part 2 of the study, in which erlotinib was added to gemcitabine and oxaliplatin (Table 1) . At dose level 1, 2 DLTs occurred. One patient was hospitalized for nausea, vomiting, and diarrhea, and another missed more than a week of treatment due to weight loss and cytopenias. This prompted deescalation to dose level 1. Accrual was slow, however, and the study was closed early because the sponsors withdrew funding. Grade 3 toxicities in the limited number of patients treated included cytopenias, nausea, vomiting, diarrhea and anorexia.
DISCUSSION
There is a persistent controversy over how best to treat locally advanced and metastatic pancreatic cancer and little convincing evidence to recommend any "new" therapy since gemcitabine was approved in the 1990s. However, a strong rationale remains for studying new chemoradiotherapy regimens. Localized disease may profoundly affect quality of life, and control of local disease may help palliate some of the most agonizing symptoms of pancreatic cancer pain, obstruction, and cachexia. XRT, using chemosensitizing agents, may have an important role in the management of local disease. Gemcitabine acts as a radiosensitizer when combined with standard XRT; however, gemcitabine doses must be reduced by approximately 10% to 30% of conventional doses, delivering suboptimal systemic drug concentrations. 1 Oxaliplatin also has radiosensitizing properties, and combinations of oxaliplatin and gemcitabine have demonstrated synergy in various studies. Combining the 2 agents in the locally advanced setting may improve systemic effect, and at the same time provide local control. We were able to demonstrate that full-dose XRT can be integrated safely into this combination regimen. The highest tested combination was gemcitabine 200 mg/m 2 and oxaliplatin 50 mg/m 2 weekly with 50.4 Gy XRT over 5 to 6 weeks, which produced manageable toxicity.
Two other recent phase I/II trials have investigated the feasibility of using oxaliplatin and gemcitabine and concurrent XRT in the treatment of pancreatic cancer. One group of investigators administered oxaliplatin (escalated to 85 mg/m 2 ), full-dose gemcitabine, and an attenuated XRT dose. Grade 3 and 4 toxicities included thrombocytopenia, worsening of performance status, gastrointestinal bleeding, and other gastrointestinal toxicities. 10 Another group administered 2 cycles of gemcitabine and oxaliplatin followed by escalating weekly doses of oxaliplatin (up to 70 mg/m 2 ), a fixed dose of gemcitabine (300 mg/m 2 ), and XRT to 45 Gy (for a total of 5 wk) with acceptable toxicity. 11 Median time to progression was 8 months and OS was 17 months.
In our study, oxaliplatin and gemcitabine were also combined at less than standard doses but with a conventional dose of XRT. There was no major toxicity at the highest planned doses of the 2 agents. Progression-free survival and OS in this study compares favorably to the survival results found in the Laurent study, 11 which was very similar in design. Recent data from a chemotherapy-first approach in locally advanced pancreatic cancer 12 suggest that perhaps a strategy of chemotherapy alone followed by chemoradiation for patients who do not progress systemically is an approach with the best tradeoff between efficacy and minimization of toxicity. A gemcitabine/oxaliplatin/XRT combination would be worth exploring within such a trial.
Our experience with erlotinib was limited by trial closure but was associated with significant toxicity at the first planned dose level. Others have had experience with erlotinib plus XRT combinations in pancreatic cancer. Iannitti et al 13 utilized a regimen of gemcitabine (75 mg/m 2 weekly), paclitaxel (40 mg/m 2 weekly) and erlotinib, with the finding that erlotinib MTD was 50 mg daily. Using a lower dose of gemcitabine of 40 mg/m 2 twice weekly, Duffy and colleagues found the MTD of erlotinib to be 100 mg daily with hematologic toxicities comprising the DLTs. OS in that study was particularly interesting at 18.7 months. 14 Tempering our enthusiasm for further study, however, is the recent experience in rectal cancer, where the addition of oxaliplatin to 5-fluorouracil-based chemoradiation has produced disappointing results. 15 In summary, gemcitabine (200 mg/m 2 weekly) and oxaliplatin (60 mg/m weekly) can be combined with standarddose radiation therapy (1.8 Gy fractions to 5040 Gy). Lower doses of chemotherapy are required if erlotinib is added, even at only 50 mg daily. OS results in this study were promising, although the group was somewhat heterogeneous and the sample size small, tempering our enthusiasm to recommend this regimen for further study.
